Michael Chiu is listed as an executive officer and director on 4 SEC Form D filings by 2 issuers between Sep 2018 and Feb 2025: Kytopen Corp. (Cambridge, MA — biotechnology — 2024–2025; $32.5M reported sold to 22 investors) and Erbi Biosystems, Inc. (Woburn, MA — other health care — 2018–2020; $2M reported sold to 4 investors).
What this means 2 separate companies raised money with this person listed as executive officer and director, over about 7 years. Across those companies the filings report $34.5M sold in total.
Listed alongside Cullen Buie (2 shared filings), Harry Lee (2 shared filings), Kevin Lee (2 shared filings), Paul Wotton (2 shared filings), Paxton Major (2 shared filings) and 5 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Michael. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 2 court cases matching the name, 1 bankruptcy case matching the name listed in Key records below.
What this means 3 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 4 public filings for Michael Chiu and found 4 differences: Form D filed 24 days after the first sale; Michael Chiu's role changed at Erbi Biosystems, Inc.: director → executive officer, director; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.